Edwards Lifesciences EW Transcatheter Aortic Valve Replacement — Net Sales
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Edwards Lifesciences in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Edwards Lifesciences’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Edwards Lifesciences's transcatheter aortic valve replacement — net sales.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Edwards Lifesciences's transcatheter aortic valve replacement — net sales?
- Edwards Lifesciences (EW) reported transcatheter aortic valve replacement — net sales of $1.2B in Q1 2026.
- How has Edwards Lifesciences's transcatheter aortic valve replacement — net sales changed year-over-year?
- Edwards Lifesciences's transcatheter aortic valve replacement — net sales increased by 14.4% year-over-year, from $1.05B to $1.2B.
- What is the long-term trend for Edwards Lifesciences's transcatheter aortic valve replacement — net sales?
- Over 4 years (2021 to 2025), Edwards Lifesciences's transcatheter aortic valve replacement — net sales has grown at a 7.0% compound annual growth rate (CAGR), from $3.42B to $4.49B.
- What does transcatheter aortic valve replacement — net sales mean?
- This metric represents the total revenue generated from the sale of transcatheter heart valve replacement systems designed for patients with structural heart disease. It serves as a primary indicator of the company's market penetration and adoption rates for minimally invasive valve replacement technologies compared to traditional surgical alternatives. As a core growth driver, this revenue stream reflects the company's ability to maintain clinical leadership and expand its footprint in the global cardiovascular device market.